Literature DB >> 27448574

Pretreatment tumor SUVmax predicts disease-specific and overall survival in patients with head and neck soft tissue sarcoma.

Seung Cheol Ha1, Jungsu S Oh2, Jong-Lyel Roh3, Hyojeong Moon2, Jae Seung Kim2, Kyung-Ja Cho4, Seung-Ho Choi1, Soon Yuhl Nam1, Sang Yoon Kim1.   

Abstract

PURPOSE: Head and neck soft tissue sarcoma (HNSTS) is a rare type of tumor with various histological presentations and clinical behaviors. 18F-FDG PET/CT is being increasingly used for staging, grading, and predicting treatment outcomes in various types of human cancers, although this modality has been rarely studied in the survival prediction of HNSTS. Here we examined the prognostic value of tumor metabolic parameters measured using 18F-FDG PET/CT in patients with HNSTS.
METHODS: This study included 36 consecutive patients with HNSTS who underwent 18F-FDG PET/CT scanning prior to treatment at our institution. Tumor gross total volume (GTV) was measured from pretreatment contrast-enhanced CT scans, and maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured using pretreatment 18F-FDG PET/CT scans. Univariate and multivariate Cox proportional hazard regression analyses were used to identify associations between imaging parameters and disease-specific survival (DSS) or overall survival (OS).
RESULTS: Univariate analyses showed that SUVmax, MTV, and TLG, but not GTV, were significantly associated with DSS and OS (all P < 0.05). After controlling for clinicopathological factors, SUVmax, MTV, and TLG were significantly associated with DSS and OS (all P < 0.05). Patients with a tumor SUVmax value of >7.0 experienced an approximately fivefold increase in mortality in terms of DSS and OS relative to those with a tumor SUVmax <7.0.
CONCLUSION: Quantitative metabolic measurements on pretreatment 18F-FDG PET/CT can yield values that are significantly predictive of survival after treatment for HNSTS.

Entities:  

Keywords:  18F-FDG PET/CT; Head and neck soft tissue sarcoma; Metabolic volume; Prognosis; Standardized uptake value

Mesh:

Substances:

Year:  2016        PMID: 27448574     DOI: 10.1007/s00259-016-3456-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  40 in total

Review 1.  Adult head and neck soft tissue sarcomas.

Authors:  Susie A Chen; Christopher G Morris; Robert J Amdur; John W Werning; Douglas B Villaret; William M Mendenhall
Journal:  Am J Clin Oncol       Date:  2005-06       Impact factor: 2.339

2.  Prognostic factors in adult soft-tissue sarcomas of the head and neck.

Authors:  Q T Le; K K Fu; S Kroll; L Fitts; V Massullo; L Ferrell; M J Kaplan; T L Phillips
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-15       Impact factor: 7.038

3.  Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer.

Authors:  Man Ki Chung; Han-Sin Jeong; Sang Gyu Park; Jeon Yeob Jang; Young-Ik Son; Joon Young Choi; Seung Hyup Hyun; Keunchil Park; Myung-Ju Ahn; Yong Chan Ahn; Hyung-Jin Kim; Young-Hyeh Ko; Chung-Hwan Baek
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

4.  Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence.

Authors:  Wolfgang P Fendler; Rebecca P Chalkidis; Harun Ilhan; Thomas Knösel; Ken Herrmann; Rolf D Issels; Peter Bartenstein; Clemens C Cyran; Lars H Lindner; Marcus Hacker
Journal:  Eur Radiol       Date:  2015-02-19       Impact factor: 5.315

5.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.

Authors:  Gerald Antoch; Nina Saoudi; Hilmar Kuehl; Gerlinde Dahmen; Stefan P Mueller; Thomas Beyer; Andreas Bockisch; Jörg F Debatin; Lutz S Freudenberg
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

6.  Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study.

Authors:  Max Lonneux; Marc Hamoir; Hervé Reychler; Philippe Maingon; Christian Duvillard; Gilles Calais; Boumédiène Bridji; Laurence Digue; Michel Toubeau; Vincent Grégoire
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

7.  Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx.

Authors:  G C Park; J S Kim; J-L Roh; S-H Choi; S Y Nam; S Y Kim
Journal:  Ann Oncol       Date:  2012-09-20       Impact factor: 32.976

8.  Head and neck soft tissue sarcomas: a multivariate analysis of outcomes.

Authors:  Brandon G Bentz; Bhuvanesh Singh; James Woodruff; Murray Brennan; Jatin P Shah; Dennis Kraus
Journal:  Ann Surg Oncol       Date:  2004-06       Impact factor: 5.344

9.  Prognostic value of metastatic nodal volume and lymph node ratio in patients with cervical lymph node metastases from an unknown primary tumor.

Authors:  G C Park; J H Jung; J-L Roh; J H Lee; K-J Cho; S-H Choi; S Y Nam; S Y Kim
Journal:  Oncology       Date:  2014-04-08       Impact factor: 2.935

10.  Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.

Authors:  Charline Lasnon; Cédric Desmonts; Elske Quak; Radj Gervais; Pascal Do; Catherine Dubos-Arvis; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-06       Impact factor: 9.236

View more
  7 in total

Review 1.  Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?

Authors:  Amani Arthur; Edward W Johnston; Jessica M Winfield; Matthew D Blackledge; Robin L Jones; Paul H Huang; Christina Messiou
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

2.  Pre-treatment metabolic tumor volume predicts tumor metastasis and progression in high-grade salivary gland carcinoma.

Authors:  Turki M Almuhaimid; Won Sub Lim; Jong-Lyel Roh; Jungsu S Oh; Jae Seung Kim; Soo-Jong Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-06       Impact factor: 4.553

3.  Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer.

Authors:  Sun Young Chae; Seol Hoon Park; Hyo Sang Lee; Jin-Hee Ahn; Sung-Bae Kim; Kyung Hae Jung; Jeong Eun Kim; Sei Hyun Ahn; Byung Ho Son; Jong Won Lee; Beom Seok Ko; Hee Jeong Kim; Gyungyub Gong; Jungsu S Oh; Seo Young Park; Dae Hyuk Moon
Journal:  Sci Rep       Date:  2022-05-12       Impact factor: 4.996

4.  Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis.

Authors:  Linyan Chen; Xin Wu; Xuelei Ma; Linghong Guo; Chenjing Zhu; Qingfang Li
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

5.  Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer.

Authors:  Sun Young Chae; Hye Joo Son; Dong Yun Lee; Eonwoo Shin; Jungsu S Oh; Seung Yeon Seo; Sora Baek; Ji Young Kim; Sae Jung Na; Dae Hyuk Moon
Journal:  EJNMMI Res       Date:  2020-05-24       Impact factor: 3.138

6.  Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma.

Authors:  Bingxin Gu; Xin Liu; Shuoer Wang; Xiaoping Xu; Xiaosheng Liu; Silong Hu; Wangjun Yan; Zhiguo Luo; Shaoli Song
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-03       Impact factor: 10.057

Review 7.  Malignant Vascular Tumors of the Head and Neck-Which Type of Therapy Works Best?

Authors:  Susanne Wiegand; Andreas Dietz; Gunnar Wichmann
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.